GRAIL (NASDAQ:GRAL) Chief Financial Officer Aaron Freidin said the company’s Galleri multi-cancer early detection test recorded strong first-half growth as it expanded distribution through digital health platforms, employers and physician offices. Speaking at the Canaccord Genuity Growth Conference

Galleri volume jumped 35% year over year on physician adoption and digital partnerships.

Why GRAIL Stock Is Back in Focus After the Galleri FDA Panel Date GRAIL (GRAL) is drawing fresh attention after regulators set a September 23, 2026 advisory committee meeting to review the Premarket Approval application for its Galleri multi cancer early detection blood test. See our latest analysis for GRAIL. The Galleri panel date and recent Q2 update appear to have sharpened attention on GRAIL, with the share price up 9.59% over one day and 12.72% over 90 days. Over the same period, the...

Medical research stocks took a bath Thursday, helped by BillionToOne's second-quarter report, featuring a beat but no guidance raise.

Moby summary of GRAIL, Inc.'s Q2 2026 earnings call

GRAIL Inc (GRAL) reports 26% revenue growth and 35% increase in test volumes, while navigating FDA advisory committee timeline and competitive pressures.

GRAIL (NASDAQ:GRAL) reported second-quarter revenue growth driven by higher Galleri test volumes, while outlining continued efforts to secure FDA approval, expand its commercial organization and build international distribution partnerships. Revenue totaled $44.7 million in the second quarter, up 2

Jazz (JAZZ) delivered earnings and revenue surprises of -5.46% and +9.33%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

The developer of blood-based cancer tests still has a bright future.

The fate of Grail's stock will ultimately be decided in the cost-benefit calculations of medical insurers.